• FEES
  • REQUEST AN APPOINTMENT
  • SUBSCRIBE TO OUR MAILING LIST
  • Contact Us
Direct Line +61 426 428 156
HealthFlex
×
  • HOME
  • i3 SERVICES
  • i3 SAMPLE PROJECTS
  • i3 REPORTS
  • i3 Clinical Trials Report
  • i3 SHOP
  • i3 PARTNERSHIPS
  • i3 QoW

SponsorStudy PhaseDrug Name/CodeClinical IndicationStatusComment
I-Mab BiopharmaPhase ITJM2Autoimmune and Inflammatory DiseasesThe FDA has approved an IND application from I-Mab Biopharma, a China-based clinical stage biopharmaceutical company for TJM2, a humanized immunoglobulin G1 (IgG1) targeting granulocyte-macrophage colony-stimulating factor (GM-CSF), currently the best-in-class potential to treat autoimmune and inflammatory diseases. This Phase I initial first-in-human (FIH) single dose study will investigate safety, tolerability, pharmacokinetics/pharmacodynamics and immunogenicity of TJM2 in healthy volunteers (including Chinese subjects) in the United States.GM-CSF is a critical pro-inflammatory cytokine that plays a pivotal role in tissue inflammation and destruction in autoimmune and inflammatory diseases such as rheumatoid arthritis and osteoarthritis.
Pfizer Inc.Phase IIb/IIIPF-06651600Moderate to Severe Alopecia Areata (AA)The sponsor's Phase IIa study met the primary efficacy endpoint in improving hair regrowth on the scalp relative to baseline at week 24 as measured by the Severity of Alopecia Tool (SALT) score (100 point scale). In addition to meeting the primary efficacy endpoint, subjects under investigation also met all secondary endpoints in the study. On the back of this positive Phase IIa data for PF-06651600, a pivotal Phase IIb/III trial will enroll an estimated 660 patients and will be a double-blind, placebo-controlled, dose-ranging study to evaluate the safety and effectiveness of PF-06651600 in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. AA is an autoimmune disease caused by the body's immune cells attacking healthy hair follicles, resulting in moderate to severe hair loss, often starting with smooth, round patches. The JAK pathways are believed to play an important role in such inflammatory processes and PF-06651600 is an oral JAK3 inhibitor that is also under investigation for the treatment of rheumatoid arthritis, Crohn?s disease and ulcerative colitis.

 

logo

i3 Consult is endowed with a broad range and depth of in-house skills with specialist expertise consolidated from a stringent selection of outsourced associates.

+61 426 428 156,+33 788914240

i3consult@i3consult.com

https://www.i3consult.com

France Office: 3 Place de l’Eglise, Liglet, Vienne, 86290. Australia Office: 1001/160 Roma Street, Brisbane, Qld. Australia 4000.

Latest News and Press Release

  • 2021 Launch: BioPitch.Live Jan 7

    To kick start 2021, i3 Consult in partnership with iClinical,...

  • A Timely i3 Quote of the Week (i3 QoW) Jul 8

    "Pandemic is not a word to use lightly or carelessly....

  • Facing the Challenges in a COVID-19 Era May 30

    First and foremost, i3 Consult hopes that you and your...

  • i3 Consult: Using block chain technology in clinical trials to better help our clients. Dec 2

    Reproducibility, data sharing, personal data privacy concerns and patient enrolment...

Get Us on Social Media

Tweet to Us on @i3_Consult

Quick Links

  • HOME
  • i3 SERVICES
  • i3 SAMPLE PROJECTS
  • i3 REPORTS
  • i3 Clinical Trials Report
  • i3 SHOP
  • i3 PARTNERSHIPS
  • i3 QoW
Copyright ©i3 Consult 2021 All rights reserved.
Click this link to view our Privacy Policy